WASHINGTON (Reuters) - GlaxoSmithKline Plc said on Friday it won U.S. approval to sell a new once- a-day formulation of its Coreg hypertension drug. The new version, Coreg CR, is designed to be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results